Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease
Sponsor: Vertex
Indication: APOL1-Mediated Proteinuric Kidney Disease
GFR: ≥25 to ≤75
Principal Investigator: Bernard Fischbach, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246